Related Experiment Video
Updated: May 7, 2026

In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
US FDA approves home-delivered tDCS for treating depression
Marom Bikson1, Andre Brunoni2, Mark S George3
1Department of Biomedical Engineering, The City College of New York, New York, NY, USA.
None:
On Dec 8, 2025, the US Food and Drug Administration (FDA) approved the Flow Neuroscience transcranial Direct Current Stimulation (tDCS) device for the treatment of "moderate to severe major depressive disorder (MDD) in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication." This represents the first FDA premarket approval (PMA) for a home-use non-invasive brain-stimulation device specifically indicated for depression treatment. This is a major regulatory milestone in non-pharmacological treatment of depression, and paves the way for additional uses and new technologies of home-based neuromodulation.
Related Concept Videos
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Therapeutic Drug Monitoring: Affecting Factors
Transdermal Drug Delivery Systems
Electroconvulsive Therapy